Climb Bio Receives FDA Fast Track Designation for Budoprutug
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 07 2026
0mins
Should l Buy CLYM?
Source: Newsfilter
- FDA Fast Track Designation: Climb Bio's anti-CD19 monoclonal antibody, budoprutug, has received Fast Track Designation from the FDA for treating primary membranous nephropathy (pMN), indicating its significant potential to address urgent therapeutic needs in this area.
- Impressive Clinical Trial Results: In a completed Phase 1b study, budoprutug achieved complete peripheral B-cell depletion in 100% of patients and serologic remission in all evaluable patients, demonstrating its strong clinical activity in treating pMN.
- Ongoing Research Plans: Climb Bio is conducting a Phase 2 global open-label dose-ranging study to evaluate the pharmacodynamics and preliminary efficacy of budoprutug, with initial data expected to be shared in the second half of 2026, further advancing its clinical development.
- Strong Market Demand: With approximately 75,000 patients in the U.S. suffering from pMN and no FDA-approved therapies available, the development of budoprutug not only meets a critical market need but also presents significant commercial opportunities for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CLYM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CLYM
Wall Street analysts forecast CLYM stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.500
Low
10.00
Averages
10.50
High
11.00
Current: 9.500
Low
10.00
Averages
10.50
High
11.00
About CLYM
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The Company is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Climb Bio Secures $110M in Private Placement
- Funding Size: Climb Bio has successfully raised approximately $110 million through a private placement with institutional investors, issuing 9.48 million shares at $9.50 each, indicating strong market confidence in its future growth.
- Pre-Funded Warrants: The offering includes pre-funded warrants for up to 2.11 million shares priced at $9.4999, with an exercise price of just $0.0001, which enhances investor participation incentives significantly.
- Transaction Timeline: The transaction is expected to close around April 29, 2026, demonstrating the company's active engagement in capital markets and its funding needs for future projects.
- Stock Price Reaction: Following the financing announcement, Climb Bio's shares rose by 8% in premarket trading, reflecting investor optimism about the company's prospects and potentially boosting its subsequent market performance.
See More
Climb Bio Secures $110M in Private Placement
- Funding Size: Climb Bio has successfully raised approximately $110 million through a private placement with institutional investors, issuing 9.48 million shares priced at $9.50 each, indicating strong market confidence in its future growth.
- Pre-Funded Warrants: The offering includes pre-funded warrants for up to 2.11 million shares priced at $9.4999, with an exercise price of just $0.0001, enhancing investor participation and interest in the offering.
- Transaction Timeline: The transaction is expected to close around April 29, 2026, providing a clear timeline for the company’s funding operations and project advancements.
- Market Reaction: Following the financing announcement, Climb Bio's shares rose 8% in premarket trading, reflecting investor optimism about the company's prospects and potentially facilitating further business expansion.
See More
Climb Bio Secures $110M in Private Placement
- Funding Size: Climb Bio has successfully raised approximately $110 million through an agreement with institutional investors, issuing 9.48 million shares priced at $9.50 each, indicating strong market confidence in its future development.
- Pre-Funded Warrants: The offering includes pre-funded warrants for up to 2.11 million shares priced at $9.4999, with an exercise price of just $0.0001, which enhances investor participation and potential returns.
- Transaction Timeline: The transaction is expected to close around April 29, 2026, providing the company with ample funding to support its research and development and market expansion plans.
- Market Reaction: Following the financing announcement, Climb Bio's shares rose 8% in premarket trading, reflecting positive investor sentiment regarding the company's growth potential.
See More
Climb Bio Secures $110M in Private Placement
- Funding Size: Climb Bio has successfully raised approximately $110 million through a private placement with institutional investors, issuing 9.48 million shares at $9.50 each, indicating strong market confidence in its future growth.
- Pre-Funded Warrants: The offering includes pre-funded warrants for up to 2.11 million shares priced at $9.4999 with a minimal exercise price of $0.0001, providing investors with additional flexibility and potentially attracting more capital inflow.
- Transaction Timeline: The transaction is expected to close around April 29, 2026, allowing Climb Bio ample time to utilize the raised funds for research and market expansion initiatives.
- Market Reaction: Following the announcement of the financing, Climb Bio's shares rose by 8% in premarket trading, reflecting investor optimism regarding the company's growth potential.
See More
Climb Bio Announces R&D Webcast for Budoprutug
- R&D Spotlight: Climb Bio will host a webcast on May 5, 2026, focusing on budoprutug, an anti-CD19 monoclonal antibody, highlighting its potential in treating B-cell mediated immune diseases, particularly primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus.
- Clinical Trial Updates: Ongoing clinical trials for budoprutug have recently completed dosing in healthy volunteers for a subcutaneous formulation, indicating its potential for durable B-cell depletion and rapid reduction of autoantibodies, which may lead to clinical remission for patients.
- Expert Participation: The event will feature Dr. David Jayne, a Professor of Clinical Autoimmunity at the University of Cambridge, who will provide insights into the scientific rationale and commercial opportunities for budoprutug, enhancing investor confidence in the program.
- Strategic Development Focus: Climb Bio's strategy emphasizes the continued development of budoprutug, aiming to expedite its market introduction through FDA Orphan Drug and Fast Track designations, addressing the growing demand for treatments for immune-mediated diseases.
See More
Climb Bio Receives FDA Fast Track Designation for Budoprutug
- FDA Fast Track Designation: Climb Bio's anti-CD19 monoclonal antibody, budoprutug, has received Fast Track Designation from the FDA for treating primary membranous nephropathy (pMN), indicating its significant potential to address urgent therapeutic needs in this area.
- Impressive Clinical Trial Results: In a completed Phase 1b study, budoprutug achieved complete peripheral B-cell depletion in 100% of patients and serologic remission in all evaluable patients, demonstrating its strong clinical activity in treating pMN.
- Ongoing Research Plans: Climb Bio is conducting a Phase 2 global open-label dose-ranging study to evaluate the pharmacodynamics and preliminary efficacy of budoprutug, with initial data expected to be shared in the second half of 2026, further advancing its clinical development.
- Strong Market Demand: With approximately 75,000 patients in the U.S. suffering from pMN and no FDA-approved therapies available, the development of budoprutug not only meets a critical market need but also presents significant commercial opportunities for the company.
See More
Climb Bio Secures $110M in Private Placement
- Funding Size: Climb Bio has successfully raised approximately $110 million through a private placement with institutional investors, issuing 9.48 million shares at $9.50 each, indicating strong market confidence in its future growth.
- Pre-Funded Warrants: The offering includes pre-funded warrants for up to 2.11 million shares priced at $9.4999, with an exercise price of just $0.0001, which enhances investor participation incentives significantly.
- Transaction Timeline: The transaction is expected to close around April 29, 2026, demonstrating the company's active engagement in capital markets and its funding needs for future projects.
- Stock Price Reaction: Following the financing announcement, Climb Bio's shares rose by 8% in premarket trading, reflecting investor optimism about the company's prospects and potentially boosting its subsequent market performance.
See More
Climb Bio Secures $110M in Private Placement
- Funding Size: Climb Bio has successfully raised approximately $110 million through a private placement with institutional investors, issuing 9.48 million shares priced at $9.50 each, indicating strong market confidence in its future growth.
- Pre-Funded Warrants: The offering includes pre-funded warrants for up to 2.11 million shares priced at $9.4999, with an exercise price of just $0.0001, enhancing investor participation and interest in the offering.
- Transaction Timeline: The transaction is expected to close around April 29, 2026, providing a clear timeline for the company’s funding operations and project advancements.
- Market Reaction: Following the financing announcement, Climb Bio's shares rose 8% in premarket trading, reflecting investor optimism about the company's prospects and potentially facilitating further business expansion.
See More
Climb Bio Secures $110M in Private Placement
- Funding Size: Climb Bio has successfully raised approximately $110 million through an agreement with institutional investors, issuing 9.48 million shares priced at $9.50 each, indicating strong market confidence in its future development.
- Pre-Funded Warrants: The offering includes pre-funded warrants for up to 2.11 million shares priced at $9.4999, with an exercise price of just $0.0001, which enhances investor participation and potential returns.
- Transaction Timeline: The transaction is expected to close around April 29, 2026, providing the company with ample funding to support its research and development and market expansion plans.
- Market Reaction: Following the financing announcement, Climb Bio's shares rose 8% in premarket trading, reflecting positive investor sentiment regarding the company's growth potential.
See More
Climb Bio Secures $110M in Private Placement
- Funding Size: Climb Bio has successfully raised approximately $110 million through a private placement with institutional investors, issuing 9.48 million shares at $9.50 each, indicating strong market confidence in its future growth.
- Pre-Funded Warrants: The offering includes pre-funded warrants for up to 2.11 million shares priced at $9.4999 with a minimal exercise price of $0.0001, providing investors with additional flexibility and potentially attracting more capital inflow.
- Transaction Timeline: The transaction is expected to close around April 29, 2026, allowing Climb Bio ample time to utilize the raised funds for research and market expansion initiatives.
- Market Reaction: Following the announcement of the financing, Climb Bio's shares rose by 8% in premarket trading, reflecting investor optimism regarding the company's growth potential.
See More
Climb Bio Announces R&D Webcast for Budoprutug
- R&D Spotlight: Climb Bio will host a webcast on May 5, 2026, focusing on budoprutug, an anti-CD19 monoclonal antibody, highlighting its potential in treating B-cell mediated immune diseases, particularly primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus.
- Clinical Trial Updates: Ongoing clinical trials for budoprutug have recently completed dosing in healthy volunteers for a subcutaneous formulation, indicating its potential for durable B-cell depletion and rapid reduction of autoantibodies, which may lead to clinical remission for patients.
- Expert Participation: The event will feature Dr. David Jayne, a Professor of Clinical Autoimmunity at the University of Cambridge, who will provide insights into the scientific rationale and commercial opportunities for budoprutug, enhancing investor confidence in the program.
- Strategic Development Focus: Climb Bio's strategy emphasizes the continued development of budoprutug, aiming to expedite its market introduction through FDA Orphan Drug and Fast Track designations, addressing the growing demand for treatments for immune-mediated diseases.
See More
Climb Bio Receives FDA Fast Track Designation for Budoprutug
- FDA Fast Track Designation: Climb Bio's anti-CD19 monoclonal antibody, budoprutug, has received Fast Track Designation from the FDA for treating primary membranous nephropathy (pMN), indicating its significant potential to address urgent therapeutic needs in this area.
- Impressive Clinical Trial Results: In a completed Phase 1b study, budoprutug achieved complete peripheral B-cell depletion in 100% of patients and serologic remission in all evaluable patients, demonstrating its strong clinical activity in treating pMN.
- Ongoing Research Plans: Climb Bio is conducting a Phase 2 global open-label dose-ranging study to evaluate the pharmacodynamics and preliminary efficacy of budoprutug, with initial data expected to be shared in the second half of 2026, further advancing its clinical development.
- Strong Market Demand: With approximately 75,000 patients in the U.S. suffering from pMN and no FDA-approved therapies available, the development of budoprutug not only meets a critical market need but also presents significant commercial opportunities for the company.
See More
